CORONARY REVASCULARIZATION by percutaneous transluminal coronary angioplasty (PTCA) has an ϳ90% success rate immediately posttreatment (5). However, the procedure causes vascular injury by endothelial denudation and stretching of the vascular wall, leading to inward vascular remodeling. Endothelial cell (EC) removal exposes the underlying medial vascular smooth muscle cell (VSMC) layer to circulating growth factors and inflammatory cytokines, including platelet-derived growth factor (PDGF), thrombin, thromboxane A 2 , and adenosine diphosphate released from accumulating platelets (5). PDGF and thrombin are potent stimuli for VSMC proliferation and migration. Adenosine diphosphate binding to the platelet P2Y 12 receptor causes enhanced platelet activation, thereby facilitating further PDGF release, as well as amplification of the response to thromboxane A 2 and thrombin, thus playing a central role in thrombus formation. Balloon dilation stretches the vascular wall, resulting in activation of stretch-activated signaling pathways in medial VSMC and the adventitia, which results in further VSMC migration and proliferation. Consequently, vascular injury associated with PTCA often results in reocclusion of the artery, or restenosis, characterized by neointima formation and constrictive inward remodeling mediated by VSMC migration across the internal elastic lamina, VSMC proliferation, and extracellular matrix deposition.
activating platelets, which has led to ϳ20% reduction in DES use. Thus significant research effort has been concentrated on identifying new molecular targets for use in DES stents. Torella et al. (6) convincingly demonstrated that the p85␣ regulatory subunit of phosphoinositol 3-kinase (PI3K) phosphorylated on the protein kinase A (PKA)-dependent serine 83 (Ser83) significantly reduced neointima formation, but did not prevent endothelial regeneration following rat carotid balloon injury. They further showed that this was mediated by selective inhibition of VSMC, but not EC, proliferation. While the immediate upstream activator of PKA, cAMP blocked both EC and VSMC proliferation in cell culture, Ser83-phosphorylated p85␣ (pSer83-p85␣) selectively blocked only VSMC proliferation. Inhibition of EC proliferation by cAMP was, in contrast, pSer83-p85␣ independent. These findings identify p85␣ as a possible focal point of cAMP/PKA signal divergence and integration, with distinct signaling pathways in ECs vs. VSMCs, which blocks VSMC but not EC proliferation, thereby preventing restenosis, while promoting endothelial regeneration.
Torella et al. (6) further investigated signaling events triggered by pSer83-p85␣ overexpression in EC and VSMC cell culture and demonstrated that pSer83-p85␣ binds to Ras and inhibits ERK-1/2 activation in VSMCs but not in ECs. These results suggest a cAMP-and PKA-independent but ERK-1/2-dependent mechanism of EC proliferation, suggesting that EC and VSMC proliferation are regulated by multiple redundant pathways, among which ERK-1/2 activation is inessential for EC, but essential for VSMC, proliferation. Regulation of ERK-1/2 activation and cell proliferation by cAMP/PKA is somewhat controversial and may be cell type specific and dependent on interactions with additional signaling pathways. Alternatively, these findings may suggest regulation of p85␣ itself by additional distinct pathways in ECs vs. VSMCs. For example, p85␣ phosphorylation on Ser83 has been shown to be required for cAMP-but not PDGF-dependent PI3K activation (1) . Local PDGF levels are highly elevated in response to vascular injury, which may have pronounced consequences on clinical applicability of pSer83-p85␣, as it may change the extent of downstream signaling activation, including Akt, which could alter cellular response. Cross-talk between signaling pathways is a key determinant of cellular function, and the complexity of cross-talk between signaling pathways in vivo is often greater than in cell culture. Thus understanding the mechanisms that activate p85␣ and mediate the effects of pSer83-p85␣ in vivo is of special importance to possible clinical utility.
It is becoming increasingly clear that signaling by cyclic nucleotides is highly dependent on intracellular compartmentalization and aggregation of signaling cascades within specific microdomains. These depend on the particular combination of extracellular stimuli and can lead to opposing cellular responses (3). Thus it is possible that cAMP is compartmentalized in microdomains with different casts of signaling characters in VSMCs vs. ECs. Also, concentrations of cyclic nucleotides vary significantly in ECs vs. VSMCs in vivo, especially in response to vascular injury (3). Interestingly, Torella et al. (6) demonstrated that wild-type p85␣ and pSer83-p85␣ had identical effects on Akt, Ras, and ERK-1/2 activation, as well as on EC and VSMC apoptosis and proliferation. However, pSer83-p85␣ decreased neointima formation in response to carotid injury, but wild-type p85␣ did not. A great degree of cross-talk exists between cAMP, cGMP, and their respective phosphodiesterases (PDEs). First, PDE expression in ECs vs. VSMCs differs, with VSMCs expressing primarily PDE1, -3, and -5, and ECs expressing a wider variety of PDEs (3). Second, PDE activity is dependent on cyclic nucleotide concentrations. The activity of PDE3, a cAMP-specific PDE, is blocked by high cGMP levels, but the activity of PDE5, a cGMP-specific PDE, is stimulated (3). Dedifferentiated, proliferating VSMCs have low-cGMP levels, which could activate PDE3 and decrease cAMP levels in VSMCs, but not in ECs. Also, expression of PDE1C, a dual-specificity PDE, has been shown to be elevated in response to vascular injury (3). Thus cAMP concentrations are influenced by cGMP and altered in phenotypicaly modified VSMCs. Since PDE5 inhibitors are used for treatment of pulmonary hypertension and erectile dysfunction, the study of consequences of interaction between elevated cGMP and pSer83-p85␣ in vascular injury would be clinically important.
The PI3K family consists of several isoforms with respect to its regulatory p85 and catalytic p110 subunits. The p85␣ is the most abundant isoform, which can interact with p110␣ or -␤, but not -␥ (2). Expression of the p110 isoforms varies greatly between cell types. In the vasculature, p110␣ is highly expressed in ECs and VSMC, but p110␥ expression is moderate in ECs and low in VSMCs (4) . Activation of p110␣ is highly spatially restricted, while activation of p110␥ does not appear to be (4). Consequently, interaction between different p85 and p110 subunits differentially activates or inhibits various signaling pathways. All PI3K holloenzymes activate Akt, but the effect on other signaling pathways is isoform dependent. For example, p110␥ activates Akt, Ras, and ERK-1/2, but p110␣ inhibits ERK-1/2 activation (2). Also, different PI3K isoforms are activated by different upstream signaling (2). Thus p85␣ binding to different p110 subunits, as well as simultaneous activation of p110␥-coupled p85 subunits, in VSMCs vs. ECs might also account for opposite effects of pSer83-p85␣ on VSMCs vs. ECs.
In the study by Torella et al. (6), pSer83-p85␣ activated Akt in cultured VSMCs and ECs. They speculate that reduction in VSMC proliferation, despite Akt activation, might be due to pSer83-p85␣ activating Akt-dependent antiapoptotic pathways, but not Akt-dependent cell-cycle control. It is also possible that the cell cycle is predominantly regulated by other signaling pathways in ECs, but not in VSMCs. Also, pSer83-p85␣ might differentially regulate protein kinase D1, which is required to fully activate Akt by phosphorylating it on Thr308, which was not investigated in their study.
Another question is raised by reduction in neointima formation in response to pSer83-p85␣ of ϳ65% compared with the 90% inhibition in response to rapamycin. One possibility is that pSer83-p85␣ is less effective at reducing VSMC proliferation. However, since cell migration is primarily responsible for neointima formation over a 14-day time course used in the study by Torella et. al. (6) , an alternative consideration could be that this difference is due to pSer83-p85␣'s effect on VSMC migration, which might be lesser or temporally distinct from that of mammalian target of rapamycin inhibition. Thus evaluation of VSMC migration and the signaling pathways that regulate it in response to pSer83-p85␣ is critical, since maximal reduction in luminal narrowing is of primary importance in interventional revascularization.
In conclusion, Torella et al. (6) identify pSer83-p85␣ as a signaling intermediate that reduces restenosis while allowing for endothelial regeneration following balloon-induced vascular injury. However, p85␣ regulation and the regulation of downstream signaling and cellular responses in vivo are likely complex and may be further complicated in response to vascular injury by its interaction with additional signaling cascades. These in vivo interactions remain unknown. Finally, patients undergoing PTCA have advanced coronary artery disease, and a large percentage suffers from the metabolic syndrome or its component pathologies, type 2 diabetes, hypertension, obesity, and dyslipidemia, all of which have been correlated with increased oxidative stress and profound endothelial dysfunction. These two underlying factors are known to alter intracellular signal transduction. Thus the potential for use of pSer83-p85␣ as a therapeutic agent in DES should be carefully evaluated in animal models, which mimic these pathologies.
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